CN101267817A - 氨基酸及其应用 - Google Patents
氨基酸及其应用 Download PDFInfo
- Publication number
- CN101267817A CN101267817A CNA2006800343838A CN200680034383A CN101267817A CN 101267817 A CN101267817 A CN 101267817A CN A2006800343838 A CNA2006800343838 A CN A2006800343838A CN 200680034383 A CN200680034383 A CN 200680034383A CN 101267817 A CN101267817 A CN 101267817A
- Authority
- CN
- China
- Prior art keywords
- proline
- free
- supplement
- milligrams
- effective dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 title description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 64
- 229960002429 proline Drugs 0.000 claims abstract description 64
- 229930182821 L-proline Natural products 0.000 claims abstract description 53
- 239000013589 supplement Substances 0.000 claims abstract description 43
- 208000005156 Dehydration Diseases 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000018044 dehydration Effects 0.000 claims abstract description 15
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 230000037396 body weight Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000015897 energy drink Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 230000037067 skin hydration Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000237890 Haliotis Species 0.000 description 1
- 241000143513 Haliotis roei Species 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种补充剂、其用途,以及用于补充生物中游离细胞L-脯氨酸浓度,用于限制该生物脱水的方法,包含有效量的游离L-脯氨酸的补充剂。该补充剂在降低经历水应激的生物中自由基水平中是有效的。本发明进一步涉及一种治疗人和动物脱水的方法,其包括给予需要此治疗的个体有效量的一种根据本发明第三方面的补充剂的步骤。有效量的游离L-脯氨酸通常是20~1000毫克,优选100毫克游离L-脯氨酸/千克生物体重,一天三次。
Description
技术领域
本发明涉及氨基酸及其用途。本发明进一步涉及用于治疗人和动物的组合物和方法以及该氨基酸的用途。
背景技术
水是维持生命的必需分子,并且动物应对其体内含水量变化的能力对于其生存是极为重要的。体内水分的损失是所有动物共有的一种威胁。这类损失可通过蒸发、废物排泄或渗透发生。渗透通常发生在盐水环境中,如海水,或通过细胞外冷冻发生,或因疾病,例如糖尿病或高血糖症引起,其引起渗透失衡。
在人类中,水分损失通过呼吸、出汗、排尿以及其它过程发生。这种水分损失在锻炼、高温和干燥的环境条件中加剧。作为水分损失和氧化应激的结果,细胞内自由基水平增加,导致细胞损伤,并且如果这一过程不被抑制,常常是非常致命的。
牛磺酸是一种基于硫的非蛋白质氨基酸,并且已知在脱水情况中起渗质的作用。牛磺酸通过作为抗氧化剂、钙调节剂、突触神经调质和膜稳定剂而起作用,也被称为细胞保护剂。为此,众所周知在人类消费的能量饮料中包括牛磺酸。
众所周知,如EP 1 514 554 A1所公开的,在保持适当的皮肤水合作用中,除了其它成分如神经酰胺和鱼软骨水解产物外,还口服使用了L-脯氨酸。然而,至今也没有认可L-脯氨酸是一种抗氧化剂或自由基清除剂。
现已显示,当淡水和咸水动物暴露于高渗透压时,L-脯氨酸的浓度增加。还已知,在低盐浓度时,L-脯氨酸从澳洲鲍(Haliotis roei)的细胞释放以维持细胞容积。因此,L-脯氨酸通常被认为是动物细胞的一种细胞内渗透物,但是至今,大多数研究都集中在当将生物置于高渗透压下时,L-脯氨酸的细胞内产生和分泌上。然而,现有技术的不足是发表的现有技术的研究中没有一个涉及在预防和/或治疗置于高渗透压下的生物的脱水和自由基增加中使用游离L-脯氨酸补充的。
EP 1 514 554 A1公开了一种基于天然物质的组合物,该组合物适用于维持适当的皮肤水合作用和防止和/或治疗皮肤衰老的效应,特别是皱纹,其特征在于它联合包含以稻(Oryza sativa)提取物形式的神经酰胺;鱼软骨水解产物,以及一种或多种选自L-脯氨酸、L-亮氨酸、L-缬氨酸和L-半胱氨酸的氨基酸。所述组合物包含20-200毫克/天,优选40毫克/天这些氨基酸。该组合物的不足是所建议的L-脯氨酸水平不足以升高细胞游离L-脯氨酸的浓度至当使用者暴露于水分和热应激时抑制其中脱水和自由基浓度降低的程度。
发明内容
发明目的
因此,本发明的目的是提供一种补充剂和可以使用该补充剂减轻上述不足的方法,并提供L-脯氨酸的新用途。
发明概述
根据本发明的第一方面,提供了有效量的游离L-脯氨酸在制备用于补充生物中游离细胞L-脯氨酸浓度、用于限制该生物脱水的补充剂中的用途。
所述补充剂可以通过提供20毫克~1000毫克游离L-脯氨酸/千克受益于其应用的生物体重来制备,呈经口施用的形式。
所述补充剂可以通过混合100毫克游离L-脯氨酸/千克受益于其应用的生物体重与一种适于人类消费的饮料混合来制备。
根据本发明的第二方面,提供了有效量的游离L-脯氨酸作为用于补充生物中游离细胞L-脯氨酸浓度、用于限制该生物脱水的补充剂的用途。
所述补充剂可以包含20毫克~1000毫克游离L-脯氨酸/千克受益于其应用的生物体重,呈经口施用的形式。
所述补充剂可以包含100毫克游离L-脯氨酸/千克受益于其应用的生物体重,其与一种适于人类消费的饮料混合。
根据本发明的第三方面,提供了一种用于补充生物中游离细胞L-脯氨酸浓度、用于限制该生物脱水的补充剂,所述补充剂包含有效量的游离L-脯氨酸。
上述补充剂可以有效降低经历水应激的生物内的自由基水平。
有效量的L-脯氨酸可以在经口施用中包含20毫克~1000毫克游离L-脯氨酸/千克受益于其应用的生物体重。
有效量的L-脯氨酸可以包含100毫克游离L-脯氨酸/千克受益于其应用的生物体重,其与一种适于人类消费的饮料混合。
根据本发明的第四方面,提供了一种治疗人和动物脱水的方法,其包括给予需要此治疗的个体有效量的根据本发明第三方面的补充剂的步骤。
在一个实施方案中,所述生物是人,并且游离L-脯氨酸浓度通过口服给予有效量的游离L-脯氨酸来补充,以对抗该人的脱水。应当理解,当被给与补充剂的人由于运动、热或缺乏水摄入而经历水应激时,这种补充是特别需要和有效的。人们进一步意识到:当预防性服用补充剂时,补充剂在增加该人中的游离L-脯氨酸浓度和水的水平中将是有效的。
根据本发明的第五方面,提供了一种补充生物中游离细胞L-脯氨酸浓度,用于限制该生物脱水的方法,其包括给予该生物有效量的游离L-脯氨酸的步骤。
游离L-脯氨酸的有效量可能为20毫克~1000毫克,优选100毫克游离L-脯氨酸/千克生物体重,一天三次。
具体实施方式
实施例
根据本发明优选的实施方案,用于限制人类脱水和降低细胞自由基浓度的有效量的补充剂通过将100毫克游离L-脯氨酸/千克人体重与任何常规现货供应的能量或冷饮混合来制备。
因此,一个体重80千克的成年男性,补充剂通过将8克游离L-脯氨酸与500毫升能量饮料混合来制备。成年男性一日三次口服所述补充剂。
已发现,使用补充剂导致使用者细胞游离L-脯氨酸的浓度增加,并且提高的浓度同样可以保持。
进一步令人意外地发现,补充剂实质上减少了使用者的失水和脱水,特别是当暴露于热和水应激以及锻炼过程中时。
可以预见,根据本发明的补充剂在预防和治疗人和动物脱水领域会有广泛的应用,如用于预防极限运动员的脱水;在病人中用作水合滴剂的补充剂(包括儿科应用);用于在国际运输前增强观赏鱼的饲料;以及用于在屠宰和冷冻前增强羊、牛、家禽、鱼和其它动物的饲料。
应当理解,本发明的细节变化是可能的,而没有偏离所附权利要求的范围。
Claims (22)
1.有效量的游离L-脯氨酸在制备用于补充生物中游离细胞L-脯氨酸浓度、用于限制该生物脱水的补充剂中的用途。
2.根据权利要求1的用途,其中所述补充剂通过提供20毫克~1000毫克游离L-脯氨酸/千克受益于其应用的生物体重来制备,呈经口施用的形式。
3.根据权利要求2的用途,其中所述补充剂通过将100毫克游离L-脯氨酸/千克受益于其应用的生物体重与适于人类消费的饮料混合来制备。
4.有效量的游离L-脯氨酸作为用于补充生物中游离细胞L-脯氨酸浓度、用于限制该生物脱水的补充剂的用途。
5.根据权利要求4的用途,其中所述补充剂包含20毫克~1000毫克游离L-脯氨酸/千克受益于其应用的生物体重,呈经口施用的形式。
6.根据权利要求5的用途,其中所述补充剂包含100毫克游离L-脯氨酸/千克受益于其应用的生物体重,其与适于人类消费的饮料混合。
7.一种用于补充生物中游离细胞L-脯氨酸浓度、用于限制该生物脱水的补充剂,该补充剂包含有效量的游离L-脯氨酸。
8.根据权利要求7的补充剂,其有效降低经历水应激的生物中的自由基水平。
9.根据权利要求7或权利要求8的补充剂,其中所述有效量的L-脯氨酸包含20毫克~1000毫克游离L-脯氨酸/千克受益于其应用的生物体重,呈经口施用的形式。
10.根据权利要求7或权利要求8的补充剂,其中所述有效量的L-脯氨酸包含100毫克游离L-脯氨酸/千克受益于其应用的生物体重,其与适于人类消费的饮料混合。
11.一种治疗人类和动物脱水的方法,其包括给予需要此治疗的个体有效量的根据权利要求7-10任意一项的补充剂的步骤。
12.根据权利要求11的方法,其中所述生物是人,并且游离L-脯氨酸浓度通过口服有效量的游离L-脯氨酸来补充,以对抗该人的脱水。
13.根据权利要求12的方法,其中被给予所述补充剂的人由于运动、热或缺乏水摄入而经历水应激。
14.根据权利要求11或权利要求12的方法,其中所述补充剂是预防性服用,并有效增加所述人类中游离L-脯氨酸的浓度和水的水平。
15.一种补充生物中游离细胞L-脯氨酸的浓度、限制该生物脱水的方法,其包括给予该生物有效量的游离L-脯氨酸的步骤。
16.根据权利要求9的方法,其中所述游离L-脯氨酸的有效量是20毫克~1000毫克/千克受益于其应用的生物体重,一天三次。
17.根据权利要求10的方法,其中所述游离L-脯氨酸的有效量是100毫克游离L-脯氨酸/千克生物体重,一天三次。
18.实质上如本文所述和举例说明的游离L-脯氨酸在制备补充剂中的用途。
19.实质上如本文所述和举例说明的游离L-脯氨酸作为补充剂的用途。
20.实质上如本文所述和举例说明的补充剂。
21.实质上如本文所述和举例说明的治疗脱水的方法。
22.实质上如本文所述和举例说明的补充生物中游离细胞L-脯氨酸浓度的方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA2005/07602 | 2005-09-20 | ||
ZA200507602 | 2005-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101267817A true CN101267817A (zh) | 2008-09-17 |
Family
ID=37670721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800343838A Pending CN101267817A (zh) | 2005-09-20 | 2006-09-19 | 氨基酸及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100099734A1 (zh) |
EP (1) | EP1931333A1 (zh) |
CN (1) | CN101267817A (zh) |
AU (1) | AU2006293520A1 (zh) |
WO (1) | WO2007034401A1 (zh) |
ZA (1) | ZA200801664B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012169600A1 (ja) * | 2011-06-07 | 2012-12-13 | 味の素株式会社 | アミノ酸組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7584891A (en) * | 1990-03-19 | 1991-10-21 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
GB9114202D0 (en) * | 1991-07-01 | 1991-08-21 | Quadrant Holdings Cambridge | Blood products |
CA2164686A1 (en) * | 1994-12-07 | 1996-06-08 | Ajinomoto Co., Inc. | Antihepatitis agent |
WO2003075903A2 (en) * | 2002-03-08 | 2003-09-18 | Universiteit Leiden | Use proline and its functional equivalentsfor quenching ros and/ or radicals |
ITTO20030672A1 (it) * | 2003-09-03 | 2005-03-04 | Medestea Internaz S R L | Composizione a base di sostanze naturali utile nel |
-
2006
- 2006-09-19 CN CNA2006800343838A patent/CN101267817A/zh active Pending
- 2006-09-19 EP EP06809330A patent/EP1931333A1/en not_active Withdrawn
- 2006-09-19 US US11/992,178 patent/US20100099734A1/en not_active Abandoned
- 2006-09-19 AU AU2006293520A patent/AU2006293520A1/en not_active Abandoned
- 2006-09-19 WO PCT/IB2006/053353 patent/WO2007034401A1/en active Application Filing
-
2008
- 2008-02-20 ZA ZA200801664A patent/ZA200801664B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1931333A1 (en) | 2008-06-18 |
WO2007034401A1 (en) | 2007-03-29 |
US20100099734A1 (en) | 2010-04-22 |
AU2006293520A1 (en) | 2007-03-29 |
ZA200801664B (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2599362A1 (en) | Hangover remedy and alcohol abatement composition | |
Saha et al. | Selenium in animal nutrition: deficiencies in soils and forages, requirements, supplementation and toxicity | |
LT5657B (lt) | Melsvadumblio spirulina platensis konservavimas natūraliu bičių medumi | |
CN101861153A (zh) | 腹膜透析液 | |
DE202012011540U1 (de) | Nahrungsmittelzusammensetzung mit Aminosäuren und Kakao | |
Suárez et al. | Effect of amaranth proteins on the RAS system. In vitro, in vivo and ex vivo assays | |
RU2463811C1 (ru) | Специализированный продукт для питания спортсменов | |
Hancz et al. | Improving the nutritional value of Nile tilapia fillet by dietary selenium supplementation | |
CA2571156C (en) | Electrolyte supplement and method of use | |
Sahiti et al. | Metal accumulation and effect of vitamin C and E in accumulated heavy metals in different tissues in common carp (Cyprinus carpio) treated with heavy metals | |
Sharma et al. | Protective effect of Spirulina and tamarind fruit pulp diet supplement in fish (Gambusia affinis Baird & Girard) exposed to sublethal concentration of fluoride, aluminum and aluminum fluoride | |
CN105878397A (zh) | 一种调节牛羊运输应激组合物 | |
KR20070031815A (ko) | 사료첨가제 및 이 사료첨가제가 배합된 사료로 사육된 가축 | |
CN101267817A (zh) | 氨基酸及其应用 | |
KR100707848B1 (ko) | 천연식이유황과 비타민 c를 함유하는 유황 축적 증대용 양계용 영양액, 그 영양액의 제조방법, 그 영양액 의한 닭의 사육방법, 그 사육 방법으로 사육된 닭, 및 그 닭에 의해 생산되는 천연식이유황이 함유된 계란 | |
US10226513B2 (en) | Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration | |
Nielsen et al. | A marine mineral supplement alters markers of bone metabolism in yearling arabians | |
Adebiyi et al. | Performance evaluation and bone characteristics of growing cockerel fed diets containing different levels of diatomaceous earth | |
Gushcha et al. | Pathogenetic and sanogenetic mechanisms of the influence of mineral waters (siliconed and with increased organic substances) of different osmularity on the exposure of toxic nephritis | |
CN109170913A (zh) | 一种含燕窝肽、大豆肽和牦牛骨胶原肽的保健组合物 | |
CN1312179C (zh) | 一种通过调节酸碱度使淡水鱼皮胶原蛋白改性的方法 | |
US20100316732A1 (en) | Beverage compositions for the promotion of joint health in companion animals | |
US20110195158A1 (en) | Wildlife nutritional supplementation and methods for making the same | |
Fajt et al. | The significance of pork as a source of dietary selenium—an evaluation of the situation in the Czech Republic | |
Smirnova et al. | Red beetroot juice and stamina: An experimental study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1125033 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080917 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1125033 Country of ref document: HK |